A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD

Trial Profile

A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs OPT 302 (Primary) ; Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; First in man
  • Sponsors Opthea
  • Most Recent Events

    • 20 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
    • 15 Aug 2017 According to an Opthea media release, results were presented at the American Society for Retinal Specialists (ASRS) meeting.
    • 15 Aug 2017 Additional results published in an Opthea Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top